Cenduit keeps the medicine moving

An oncology trial was already running when its sponsor discovered an awkward fact: the software could not run the trial it had bought it to run. Dose levels would change. Patient cohorts would change. The medication-management algorithm could not keep up. Cenduit was asked to replace the system while the study continued.

The case is instructive because the failure appeared after go-live. The sponsor’s adaptive design needed flexibility the original tool could not provide. A request for proposals followed. The replacement required data mapping, testing, site training, and a controlled changeover. IQVIA’s account says the trial kept its original schedule. For a business built around clinical logistics, a successful ending can be remarkably uneventful.

“they’ve also kept the study running within the original schedule.”

Senior clinical trial supply manager
Unnamed oncology sponsor, published case study

Cenduit’s role becomes clearer at this point. A treatment assignment has consequences outside the database. Someone needs a usable kit, in a usable place, for a particular visit. If a study changes, the instructions governing that kit must change with it. A beautifully organized screen is little consolation when it describes a world the trial has already left behind.

The statistician meets the medicine cabinet

Cenduit, now operating as IQVIA IRT, specializes in interactive response technology. The initials describe the software category; randomization and trial supply management, or RTSM, describes much of the work. It sits where a study’s allocation rules meet its physical inventory. Sponsors and contract research organizations purchase the service. Research sites, supply managers, and monitors live with the decisions it helps administer.

Randomization assigns participants to treatment groups according to the study design. Blinding limits who can see those assignments. Supply management makes the appropriate treatment available without turning every site into a warehouse. The operations are related: a randomization decision can create a dispensing need, and dispensing changes the inventory available for the next visit.

An older Cenduit white paper offers a pleasingly concrete example. In a six-month study with monthly visits, a site could initially receive one or two visits’ worth of medicine per patient rather than the entire course. The system directs staff to the appropriate pack at each visit. If someone leaves early, fewer packs have been committed unnecessarily. The elegance lies in leaving options open while the actual study unfolds.

Two parents, and a head start

Cenduit began in May 2007 as a joint venture between Quintiles and Thermo Fisher Scientific. Each supplied $4 million in initial cash. They also contributed existing IRT operations: Quintiles brought teams in India and the United States; Thermo Fisher brought Fisher Clinical Services operations in the United Kingdom, United States, and Switzerland.

That origin helps explain the specialty. Clinical development and clinical supply arrived together, with working operations attached. The launch announcement described a platform combining telephone response, web interfaces, and handheld electronic patient diaries. The interfaces now sound like a small museum of computing. The problem underneath them has aged rather better: a trial has to coordinate people, rules, and medicine.

There are small glimpses of how that work develops. Cenduit’s 2019 hackathon centered on improving the site experience. In IQVIA’s published biography, delivery leader Nikki Pfammatter started as a helpdesk associate, then moved through client services and system design before leading global project managers and consultants. A support desk provides a particular education: it tells you where an elegant design becomes somebody else’s afternoon problem.

The price of having too much

Clinical supply has two costly extremes. A shortage can interrupt a patient’s treatment schedule. Excess stock can expire unused. In an April 2023 explanation, Cenduit supply specialist Stefan Duerr argued for study-specific supply strategies informed by real-time data. Shipment lead times, site demand, and the wider depot network all matter. Sending more medicine everywhere is an expensive way to postpone thinking.

IQVIA’s Supply Automation Value Engine, SAVE, addresses that balancing act. Its published examples report annual drug and shipping savings between $150,000 and $1 million. In one partner’s case, one year’s study savings exceeded the IRT cost by three times. Those are selected company-reported outcomes. They describe what happened under particular conditions, rather than what every buyer should expect.

The commercial model pairs technology with study delivery. The buyer needs a configured system, validation, project oversight, amendments, and support over the study’s life. A useful cost comparison therefore includes the work around the software: staff time, avoidable shipments, product waste, and the effort required to accommodate changes. A license figure alone would leave much of the transaction out of view.

Small trials have complicated lives, too

The newer early phase offering tackles a different purchasing objection. Phase I studies often have few participants and tight budgets. Some are open-label, so blinding is unnecessary. IQVIA’s August 2025 account explains why teams have historically used spreadsheets: the setup cost and rigidity of traditional IRT could be hard to justify.

Changing cohorts, arms, doses, and visit schedules can alter that calculation. IQVIA describes self-service tools that let teams adjust those elements during a live study, reducing the need for custom development. The buying question is whether the operational complexity warrants the implementation effort. A small participant count does not, by itself, make a study simple.

Cell and gene therapy adds another kind of difficulty. IQVIA’s May 2025 article describes treatments tailored to individual patients, with precise tracking and temperature requirements across the supply chain. Here, stock is less interchangeable. Consultation about the actual treatment journey matters because the movement of the medicine is part of what must be controlled.

Put an amendment in the demonstration

Cenduit occupies an established market. ISR’s 2025 report places IQVIA IRT alongside systems from Almac, 4G Clinical, Endpoint Clinical, Suvoda, Medidata, and Veeva, among others. The comparison is about fit: integration, site usability, startup speed, and delivery experience. A provider’s ability to handle your difficult scenario deserves more attention than the polish of its easiest one.

IQVIA’s current proposition combines a modular cloud system with trial and supply specialists. Its April 2026 fact sheet describes more than 140 pre-validated components and a dedicated project manager across design, implementation, and maintenance. The practical attraction is reuse with experienced oversight. The configuration still has to match the protocol; a component library cannot decide that match on the sponsor’s behalf.

There is a useful discipline readers can borrow from the rescue story. Bring a realistic amendment into the selection process. Ask the team to walk through what happens to the next patient visit, the kit inventory, and the historical record. Include the people who will operate the system. The exercise turns an abstract claim about flexibility into something that can be examined.

Inspection readiness belongs in that conversation. IQVIA quality director Justine Koor’s July 2025 guidance emphasizes clear responsibilities, evidence of validation, accessible records, and training. Software can record a decision; an organization must still know who owns it. Automation works best when the underlying information and responsibilities are sound.

The June 2026 supply-chain article carries the same idea forward: use changing enrollment and inventory information to revise supply decisions continuously. For Cenduit’s successors, the next delivery remains the point where the whole arrangement is tested. The patient arrives. The medicine must be there. All the cleverness has to survive that appointment.